Tag: third quarter

NORTH LIBERTY, Iowa, June 13, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Heartland Express, Inc. (Nasdaq: HTLD) announced today the declaration of a regular quarterly cash dividend. The $0.02 per share dividend will be paid on July 3, 2025, to shareholders of record at the close of business on June 23, 2025. We currently estimate that a total of $1.6 million will be paid on the Company's approximate seventy-eight million shares of common stock. This is the Company's eighty-eighth consecutive quarterly cash dividend. With the payment of this dividend, the Company will have paid a total of $558.3 million in cash dividends, including four special dividends since the dividend program was implemented in the third quarter of 2003.

STATEN ISLAND, New York, June 13, 2025 (GLOBE NEWSWIRE) -- Coffee Holding Co., Inc. (Nasdaq: JVA) (the “Company,” “our” or “we”) announced its operating results for the fiscal quarter ended April 30, 2025.

NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Lamb Weston Holdings, Inc. (NYSE: LW) on behalf of long-term stockholders following a class action complaint that was filed against Lamb Weston on June 13, 2024 with a Class Period from July 25, 2023, through April 3, 2024. Our investigation concerns whether the board of directors of Lamb Weston have breached their fiduciary duties to the company.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Elevance To Contact Him Directly To Discuss Their Options

Disclosure of total number of voting rights and
number of shares forming the capital
as of May 31, 2025

BRIDGEWATER, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of prednisolone acetate ophthalmic suspension, 1% sterile which references Pred Forte^®. Pred Forte and its design are trademarks of Allergan, Inc., an AbbVie company. Launch of this product is planned for the third quarter of 2025.

SkiStar AB will publish the Interim Report for the period 1 September 2024 – 31 May 2025 on Thursday 19 June 2025 at 07.00 a.m. CEST. In connection with the report SkiStar will organize a conference call with web presentation. CEO Stefan Sjöstrand and CFO Sara J Uggelberg will present and comment on the report. After the presentation there will be time for questions, both by phone and by chat in the web presentation. The presentation will be held in English.

Press Release